<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02991898</url>
  </required_header>
  <id_info>
    <org_study_id>2016LS107</org_study_id>
    <secondary_id>MT2016-17</secondary_id>
    <nct_id>NCT02991898</nct_id>
  </id_info>
  <brief_title>Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies</brief_title>
  <official_title>Adoptive Transfer of T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease After an Umbilical Cord Blood Transplant for Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center pilot study of a non-myeloablative umbilical cord blood transplant
      for the treatment of a hematological malignancy with a single infusion of T regulatory (Treg)
      given shortly after UCB transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Safety
  </why_stopped>
  <start_date type="Actual">February 16, 2017</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Intervention</measure>
    <time_frame>2 years</time_frame>
    <description>Measured by the length of Treg survival after infusion of Treg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade II-IV aGVHD</measure>
    <time_frame>Assessed weekly until day 100, then day 180, 360</time_frame>
    <description>Probability of grade II-IV aGVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade III-IV aGVHD</measure>
    <time_frame>Assessed weekly until day 100, then day 180, 360</time_frame>
    <description>Probability of grade III-IV aGVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related mortality (TRM)</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluated with descriptive statistics and plots or cumulative incidence curves if enough evaluable patients are available for time-to-event endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluated with descriptive statistics and plots or cumulative incidence curves if enough evaluable patients are available for time-to-event endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of viral and fungal infections</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluated with descriptive statistics and plots or cumulative incidence curves if enough evaluable patients are available for time-to-event endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detectable Treg cells</measure>
    <time_frame>Day 14</time_frame>
    <description>The proportion of patients with detectable Treg cells at day 14 post infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution</measure>
    <time_frame>Assessed at Day 4, weekly for 8 weeks</time_frame>
    <description>The proportion of patients with immune reconstitution. Continuous endpoints will be described by medians, ranges and interquartile ranges as well as means and standard deviations if normally distributed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>48 hours post infusion</time_frame>
    <description>Toxicity and adverse events will be classified according to NCI's Common Terminology Criteria for Adverse Events V 4.0 (CTCAE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treg Survival</measure>
    <time_frame>24 hours post infusion</time_frame>
    <description>Length of Treg survival after infusion of Treg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chimerism</measure>
    <time_frame>Day +100</time_frame>
    <description>The incidence of chimerism in patients treated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>1 year</time_frame>
    <description>The probability of survival, one year post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil Recovery</measure>
    <time_frame>Day 42</time_frame>
    <description>The incidence of neutrophil recovery in treated patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Recovery</measure>
    <time_frame>1 year</time_frame>
    <description>The incidence of platelet recovery in treated patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic GVHD</measure>
    <time_frame>1 year</time_frame>
    <description>The incidence of chronic GVHD in treated patients after one year</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Burkitt Lymphoma</condition>
  <condition>Natural Killer Cell Malignancies</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Large-cell Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <condition>Marginal Zone B-Cell Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <condition>Lymphoplasmacytic Lymphoma</condition>
  <condition>Mantle-Cell Lymphoma</condition>
  <condition>Prolymphocytic Leukemia</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Biphenotypic Leukemia</condition>
  <condition>Undifferentiated Leukemia</condition>
  <arm_group>
    <arm_group_label>Treg Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infusion of Treg</intervention_name>
    <description>Allopurinol on day -7 to day 0 Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 Fludarabine 30mg/m2 IV over 1 hour on day -6, -5, -4, -3, and -2 Total Body Irradiation 200 cGy as a single dose
Sirolimus 8mg-12mg oral loading dose followed by signle dose 4mg/day. Levels are to be monitored 3 times/week in the first week, weekly until day +60, and as clinically indicated until day +100 post-transplantation.
Mycophenolate Mofetil (MMF) 3 gram/day IV/PO divided in 2 or 3 doses. Stop MMF at day +30 or 7 days after neutrophil recovery, whichever day is later, if no acute GVHD.
DUCBT followed Tregs - double umbilical cord blood transplant (FIRST) followed by the Treg cell infusion (SECOND) no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion.</description>
    <arm_group_label>Treg Infusion</arm_group_label>
    <other_name>T regulatory cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Disease Criteria:

          -  Acute Leukemias: Must be in remission by morphology (around 5% blasts but &lt; 20% blasts
             by morphology). Also a small percentage of blasts that is equivocal between marrow
             regeneration versus early relapse are acceptable provided there are no associated
             cytogenetic markers consistent with relapse.

               -  Acute Lymphoblastic Leukemia (ALL) second or greater CR; CR1 unable to tolerate
                  consolidation chemotherapy due to chemotherapy-related toxicities; CR1 high-risk
                  ALL.

               -  High risk ALL is defined as having one of the following:

                    -  Evidence of high risk cytogenetics such as t(9;22), t(1;19), t(4;11), other
                       MLL rearrangements, IKZF1

                    -  30 years of age or older at diagnosis

                    -  White blood cell counts of greater than 30,000/mcL (B-ALL) or greater than
                       100,000/mcL (T-ALL) at diagnosis

                    -  CNS leukemia involvement during the course of disease

                    -  Slow cytologic response (&gt;10% lymphoblasts in bone marrow on Day 14 of
                       induction therapy)

                    -  Evidence of persistent immonophenotypic or molecular minimal residual
                       disease (MRD) at the end of induction and consolidation therapy

               -  Acute Myelogenous Leukemia (AML) and related precursor neoplasms: 2nd or greater
                  complete remission (CR); first complete remission (CR1) in patients &gt; 60 years
                  old; CR1 in ≤ 60 years old that is NOT considered as favorable-risk. Favorable
                  risk is defined as having one of the following:

                    -  t(8,21) without cKIT mutation

                    -  inv(16) or t(16;16) without cKIT mutation

                    -  Normal karyotype with mutated NPM1 and wild type FLT-ITD

                    -  Normal karyotype with double mutated CEBPA

                    -  Acute prolymphocytic leukemia (APL) in first molecular remission at end of
                       consolidation

               -  Biphenotypic/Undifferentiated/Prolymphocytic Leukemias in first or subsequent CR,
                  adult T-cell leukemia/lymphoma in first or subsequent CR

          -  Burkitt's Lymphoma in CR2 or subsequent CR

          -  Natural Killer Cell Malignancies

          -  Chronic Myelogenous Leukemia: all types except refractory blast crisis. Chronic phase
             patients must have failed at least two different tyrosine-kinase inhibitors (TKIs), or
             been intolerant to all available TKIs or have T315I mutation.

          -  Myelodysplastic Syndrome: IPSS INT-2 or High Risk; R-IPSS High or Very High; WHO
             classification: RAEB-1, RAEB-2; Severe Cytopenias: ANC &lt; 0.8, Anemia or
             thrombocytopenia requiring transfusion; Poor or very poor risk cytogenetics based on
             IPSS or R-IPSS definitions; therapy-related MDS. Blasts must be &lt; 5% by bone marrow
             aspirate morphology. If ≥5% blasts, patient requires chemotherapy for cytoreduction to
             &lt;5% blasts prior to transplantation.

          -  Large-Cell Lymphoma, Hodgkin Lymphoma and Multiple Myeloma with chemotherapy sensitive
             disease that has failed or patients who are ineligible for an autologous transplant.

          -  Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Marginal Zone
             B-Cell Lymphoma, Follicular Lymphoma, which have progressed within 12 months of
             achieving a partial or complete remission. Patients who had remissions lasting &gt; 12
             months are eligible after at least two prior therapies. Patients with bulky disease
             should be considered for debulking chemotherapy before transplant. Patients with
             refractory disease are eligible, unless has bulky disease and an estimated tumor
             doubling time of less than one month.

          -  Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia are eligible
             after initial therapy if chemotherapy sensitive.

          -  Patients must have undergone an autologous transplant ≤ 12 months prior to transplant
             on this study or have received multi-agent or immunosuppressive chemotherapy within 3
             months of the preparative regimen.

        Performance Status, Organ Function, Contraception Use

          -  Karnofsky score ≥ 70% (Appendix II)

          -  Adequate organ function within 14 days (30 days for cardiac and pulmonary) of
             registration on-study defined as:

               -  Renal: creatinine ≤ 2.0 mg/dL, for patient with a creatinine &gt; 1.2 mg/dL or a
                  history of renal dysfunction an estimated glomerular filtration rate ≥ 40
                  mL/min/1.73 m2 is required

               -  ALT, AST and alkaline phosphatase ≤ 5 x upper limit of normal and total bilirubin
                  ≤ 2.5 mg/dL except for patients with Gilbert's syndrome or hemolysis

               -  Pulmonary function: DLCO, FEV1, FVC ≥ 40% predicted, and absence of O2
                  requirements.

               -  Cardiac: Absence of decompensated congestive heart failure, or uncontrolled
                  arrhythmia and left ventricular ejection fraction ≥ 40%.

          -  Sexually active females of childbearing potential and males with partners of
             child-bearing potential must agree to use adequate birth control during study
             treatment.

          -  Voluntary written consent

        Inclusion Criteria:

          -  Must be ≥18, but &lt; 70 years of age with no available medically suitable 7/8 or 8/8
             sibling donor - patients ≥ 70 and ≤ 75 years of age may be eligible if they have a
             Co-Morbidity score ≤ 2(http://www.qxmd.com/calculate-online/hematology/hct-ci)

          -  UCB unit(s) composing the graft will be selected according to the current University
             of Minnesota umbilical cord blood graft selection algorithm plus an additional cord
             blood unit to be used as the source to manufacture the Treg product. This UCB unit
             must be matched at 4-6/6 to the patient, considering HLA-A, B at the antigen level and
             DRB1 at the allele level.

        Exclusion Criteria:

          -  Untreated active infection

          -  History of HIV infection

          -  Pregnant or breast feeding. The agents used in this study may be teratogenic to a
             fetus and there is no information on the excretion of agents into breast milk. Females
             of childbearing potential must have a blood test or urine study within 14 days prior
             to registration to rule out pregnancy

          -  Prior allogeneic transplantation

          -  Less than 3 months from myeloablative conditioning for autologous transplantation (if
             applicable)

          -  Evidence of progressive disease by imaging modalities or biopsy - persistent PET
             activity, though possibly related to lymphoma, is not an exclusion criterion in the
             absence of CT changes indicating progression.

          -  CML in blast crisis

          -  Large cell lymphoma, mantle cell lymphoma and Hodgkin disease that is progressing on
             salvage therapy.

          -  Active central nervous system malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Brunstein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2016</study_first_submitted>
  <study_first_submitted_qc>December 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2016</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CML</keyword>
  <keyword>MDS</keyword>
  <keyword>CLL</keyword>
  <keyword>ALL</keyword>
  <keyword>AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

